Genelux Announces Proposed Public Offering of Common Stock.

Genelux Corporation, a late clinical-stage immuno-oncology company, has commenced a proposed underwritten public offering of its common stock. The offering is subject to market and other customary closing conditions, and Lucid Capital Markets is acting as the sole book-running manager. The company expects to grant the underwriter a 30-day option to purchase up to an additional 15% of the number of shares sold.